A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence. The names of the study drugs involved in this study are: * Tagraxofusp (a type of CD123-directed cytotoxin) * Azacitidine (a type of standard of care cytidine nucleo

Trial Details

NCT ID
NCT07148180
Phase
PHASE1 / PHASE2
Sponsor
Jacqueline Garcia, MD
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Tagraxofusp
  • Azacitidine (AZA)
  • Venetoclax
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Age ≥ 18 years.
  • History of known diagnosis of Acute Myeloid Leukemia (including de novo, secondary or AML arising from MDS).
  • Subjects must be in CR, CRi, or CRh with \<5% morphologic blasts in bone marrow
  • Any evidence of CD123+ by central assessment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →